TET3 and head and neck squamous cell carcinoma: Among the 60 patients with stage I and II HNSCC, those with a methylated TET3 promoter had a shorter DFS time than those with an unmethylated TET3 promoter (log-rank test, P = 0.005) (Figure 4E).